Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
CE Wu, CF Chang, CY Huang, CT Yang, CHS Kuo… - BMC cancer, 2021 - Springer
Background Afatinib is one of the standard treatments for patients with epidermal growth
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
[HTML][HTML] Afatinib in EGFR TKI-Naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: a pooled analysis of three phase …
A Passaro, F de Marinis, HY Tu, KK Laktionov… - Frontiers in …, 2021 - frontiersin.org
Background Afatinib is approved for first-line treatment of patients with epidermal growth
factor receptor mutation-positive (EGFR m+) non-small-cell lung cancer (NSCLC). Here, we …
factor receptor mutation-positive (EGFR m+) non-small-cell lung cancer (NSCLC). Here, we …
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup …
Introduction Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death in
China. Four epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors …
China. Four epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors …
A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research …
R Noro, S Igawa, A Bessho, T Hirose, T Shimokawa… - Lung Cancer, 2021 - Elsevier
Objectives Afatinib is an effective treatment for patients with epidermal growth factor receptor
(EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, the toxicity …
(EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, the toxicity …
[HTML][HTML] Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
SY Lee, CM Choi, YS Chang, KY Lee… - … lung cancer Research, 2021 - ncbi.nlm.nih.gov
Background We investigated the clinical characteristics and treatment outcomes of Korean
patients receiving first-line afatinib for advanced epidermal growth factor receptor mutation …
patients receiving first-line afatinib for advanced epidermal growth factor receptor mutation …
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
WM Brückl, M Reck, F Griesinger… - Therapeutic …, 2021 - journals.sagepub.com
Background: Lung cancer is a leading cause of cancer-related death in Germany and
worldwide. Non-small cell lung cancer (NSCLC) comprises~ 80% of lung cancer diagnoses; …
worldwide. Non-small cell lung cancer (NSCLC) comprises~ 80% of lung cancer diagnoses; …
Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer
S Igawa, T Ono, M Kasajima, S Kusuhara… - Investigational New …, 2020 - Springer
Introduction Afatinib is used to treat patients with advanced non-small cell lung cancer
(NSCLC) harboring common EGFR mutations; however, the clinicopathological factors that …
(NSCLC) harboring common EGFR mutations; however, the clinicopathological factors that …
[HTML][HTML] Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b …
F de Marinis, KK Laktionov, A Poltoratskiy, I Egorova… - Lung Cancer, 2021 - Elsevier
Objectives Randomized controlled trials have demonstrated that afatinib is a suitable
treatment option for patients with epidermal growth factor receptor mutation-positive …
treatment option for patients with epidermal growth factor receptor mutation-positive …
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer …
K Park, JS Kim, JH Kim, YC Kim, HG Kim, EK Cho… - BMC cancer, 2021 - Springer
Background Afatinib is approved globally for EGFR-TKI treatment-naïve patients with EGFR
mutation-positive non-small cell lung cancer (NSCLC). In this Korean expanded access …
mutation-positive non-small cell lung cancer (NSCLC). In this Korean expanded access …
[HTML][HTML] The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a …
Y Zhang, S Miao, F Wang, W Fang, G Chen… - Journal of Thoracic …, 2017 - ncbi.nlm.nih.gov
Background The first generation epidermal growth factor receptor-tyrosine kinase inhibitors
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …